Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor

Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor

Mitochondria are key tumor drivers, but their suitability as a therapeutic target is unknown. Here, we report on the preclinical characterization of Gamitrinib (GA mitochondrial matrix inhibitor), a first-in-class anticancer agent that couples the Heat Shock Protein-90 (Hsp90) inhibitor 17-allylamin...

Full description

Bibliographic Details
Main Authors: Umar Hayat, Gary T. Elliott, Anthony J. Olszanski, Dario C. Altieri
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Cancer Biology & Therapy
Subjects:
mitochondria
cancer therapy
hsp90
gamitrinib
Online Access:http://dx.doi.org/10.1080/15384047.2022.2029132

Internet

http://dx.doi.org/10.1080/15384047.2022.2029132

Similar Items